Vitamin D Deficiency When Starting Treatment Linked With Increased HIV Progression

June 9, 2014

Having low levels of vitamin D when starting treatment is associated with a more than doubled risk of HIV progression, virologic failure and death, according to a recent study published in The Journal of Infectious Diseases.

The study followed 1,571 treatment-naive patients in Brazil, Haiti, India, Malawi, Peru, South Africa, Thailand, the United States and Zimbabwe. The primary endpoint was progression to WHO (World Health Organization) stage 3/4 or death within 96 weeks of starting treatment. The secondary endpoint was virologic failure (defined as two consecutive viral loads above 1,000 copies/mL after 16 weeks of starting treatment).

The researchers compared levels of baseline vitamin D to see if there was an association with increased disease progression. Data on possible vitamin D supplementation was not collected, but the researchers noted that supplementation was not common and was unlikely to have occurred in resource-limited settings. reported:

Almost half (49%) of all participants in the study had low vitamin D concentrations at baseline. Prevalence of low vitamin D varied between countries, ranging from 27% in Brazil to 78% in Thailand and 72% in India. Prevalence was 92% among African-Americans in the US.

After controlling for country and HIV treatment regimen, the factors significantly associated with low vitamin D were race, season of sampling (winter/spring), high or low body mass index (BMI) and lower HIV viral load.

Analysis that took into account history of previous AIDS-defined illness and controlled for season, baseline CD4 count and viral load, BMI and race showed that low vitamin D concentrations at the start of therapy were associated with a twofold increase in the risk of clinical disease progression (HR = 2.13; 95% CI, 1.09-4.18).

Given the results, the researchers concluded that low vitamin D levels are "common in diverse HIV-infected populations and is an independent risk factor for clinical and virologic failure," as well as HIV progression and death. They noted that further studies are needed to examine the potential benefit of vitamin D supplementation among people starting treatment.

Warren Tong is the research editor for and

Follow Warren on Twitter: @WarrenAtTheBody.

Copyright © 2014 Remedy Health Media, LLC. All rights reserved.

This article was provided by TheBodyPRO.

Reader Comments:

Comment by: Ronald Cathcart, MD (Melbourne, Florida) Tue., Jun. 17, 2014 at 10:06 am UTC
Vitamin D deficiency is extremely common among my patients (and staff). Almost all of my patients are prescribed vitamin D, usually 50,000 international units every 1 to 4 weeks. Those who have levels within the normal limits (30-100 IU) are usually highly tanned.
Reply to this comment

Comment by: Katende (Kampala , Uganda) Wed., Jun. 11, 2014 at 2:07 am UTC
Can you research be recommendation for every patient initiated on ARV to be given multivitamin tablets ? I have seen a number HIV clinic not implementing this. What is your take on this?
Reply to this comment

Comment by: Artiewhitefox (Calif,) Tue., Jun. 10, 2014 at 6:56 pm UTC
This is a bunch of gobbledygook. There is no benefit to what they are doing. All do this: Find a good UCS chiropractor in your area. One is South Africa. Upper Cervical Chiropractic Centre, Port Elizabeth, South. Doctors will be scratching their heads wondering where all the symptoms went when everyone gets the care James Tomasi talks about. Upcspine, the specific chiropractic and upper cervical heath centers. Look for upper cervical specific. Most of the places do not have UCS practitioners at all. Medical sorcerers do not want people to know how to recognize that kind of practitioner. They don't want to teach people about them at all.
Reply to this comment

Add Your Comment:
(Please note: Your name and comment will be public, and may even show up in
Internet search results. Be careful when providing personal information! Before
adding your comment, please read's Comment Policy.)

Your Name:

Your Location:

(ex: San Francisco, CA)

Your Comment:

Characters remaining:


The content on this page is free of advertiser influence and was produced by our editorial team. See our content and advertising policies.